- Overview
- Research and development
- Adaptive pathways
- Advanced therapies
- Clinical trials
- Compassionate use
- Compliance
- Data on medicines (ISO IDMP standards)
- Ethical use of animals
- Innovation in medicines
- Medicines for older people
- Non-pharmaceutical products
- Orphan designation
- Paediatric medicines
- Pharmacovigilance
- PRIME: priority medicines
- Quality by design
- Scientific advice and protocol assistance
- Scientific guidelines
- Search guidelines
- Biologicals
- Clinical efficacy and safety
- Alimentary tract and metabolism
- Blood and blood-forming organs
- Blood products
- Cardiovascular system
- Dermatologicals
- Genitourinary system and sex hormones
- Anti-infectives for systemic use
- Antineoplastic and immunomodulating agents
- Rheumatology / musculoskeletal system
- Nervous system
- Respiratory system
- Radiopharmaceuticals and diagnostic agents
- Allergy/immunology
- Biostatistics
- General
- Clinical pharmacology and pharmacokinetics
- ICH
- Multidisciplinary
- Non-clinical
- Q&A on quality
- Quality
- Marketing authorisation
- Advanced therapies
- Accelerated assessment
- Biosimilars
- Compliance
- Clinical data publication
- Conditional marketing authorisation
- Data on medicines (ISO IDMP standards)
- Generic medicines
- Guidance documents
- Orphan medicines
- Medicines for use outside EU (Article 58)
- Paediatric medicines
- Pharmacovigilance
- Pre-authorisation guidance
- Product information
- Submission dates
- Templates for assessors
- Post-authorisation
- Advanced therapies
- Compliance
- Data on medicines (ISO IDMP standards)
- Medicine shortages
- Orphan medicines
- Improving quality of submissions
- Paediatric medicines
- Parallel distribution
- Patient registries
- Pharmacovigilance
- European Risk Management Strategy
- Good pharmacovigilance practices
- Incident management plan
- Medical literature monitoring
- Medication errors
- Medicines under additional monitoring
- Periodic safety update reports
- Pharmacovigilance system
- Post-authorisation safety studies
- Regulatory and procedural guidance
- Signal management
- Post-authorisation procedural Q&A
- Regulatory and procedural guidance
- Templates for assessors
- Templates for industry
- Dossier submission requirements
- Classification of changes
- Pre-submission queries service
- Changing the name of a medicinal product
- Annual re-assessment
- Post-authorisation measures
- Renewals
- Annual renewal of conditional marketing authorisations
- PASS
- PAES
- Article 46 paediatric study submission
- Risk management plan (RMP)
- PSURs
- Transfer of marketing authorisations
- Transparency
- Article 61(3) Notifications
- Withdrawals and cessation
- Marketing and cessation notification
- Sunset clause monitoring
- Other
- Certificates for products
- Referral procedures
- Q&A: Urgent Union Procedures (Article 107i)
- Q&A: Article 13 referral procedures
- Q&A: Article 20 pharmacovigilance procedures
- Q&A: Article 20 non-pharmacovigilance procedures
- Q&A: Article 29(4) referral procedures
- Q&A: Article 30 referral procedures
- Q&A: Article 31 pharmacovigilance referrals
- Q&A: Article 31 non-pharmacovigilance referrals
- Guidance
- Variations
- Herbal products
| Current effective version | Adopted guideline |
| Reference number | CPMP/BPWG/3728/02 |
| Published | 27/07/2005 |
| Effective from | 01/02/2006 |
| Keywords | Rabies infection, rabies Ig vaccination |
| Description | This document describes the information to be included in the summary of product characteristics for human rabies immunoglobulin for intramascular use. |
Related content
How helpful is this page?
Average rating:
Based on 20 ratingsAdd your rating:
- See all ratings
-
4 ratings4 ratings4 ratings4 ratings4 ratings
RSS feed
Twitter
YouTube
